Novo Nordisk (NVO) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The SELECT-LIFE follow-up study (NCT04972721) tracks the long-term health of people with overweight or obesity who took part in Novo Nordisk’s earlier SELECT cardiovascular trial of semaglutide. It aims to see how prior use of the drug and participation in SELECT affect health and quality of life over many years, offering a broader view of real-world outcomes.
This study does not give any new medicine or active treatment. Instead, it follows former SELECT participants who once received semaglutide or placebo and now return to usual care, using surveys to understand lasting benefits, risks, and daily life impact after the trial drug stops.
SELECT-LIFE is an observational cohort study that follows a group of people over time without changing their medical care. There is no random assignment, no blinding, and no trial-driven treatment; the focus is on collecting regular health questionnaires to see how outcomes unfold in normal clinical practice.
The study first appeared on the registry on 13 July 2021, when Novo Nordisk formally set out the follow-up plan. A key milestone is that the trial is now listed as completed, and the record was most recently updated on 9 February 2026, signaling that data collection has wrapped and the program is moving toward full analysis.
Because SELECT-LIFE looks at up to 10 years of health after semaglutide exposure, any positive trends in heart health, weight, or survival could support the durability profile of Novo Nordisk’s obesity franchise. Strong long-run data would likely bolster investor confidence in NVO, pressure rivals in the GLP-1 space such as Eli Lilly, and reinforce the view that obesity drugs are a structural growth story rather than a short-term fad.
If the follow-up suggests benefits fade quickly once treatment stops or highlights safety concerns, the read-through could temper peak sales expectations and increase volatility around future obesity launches. Either way, the completion and recent update of SELECT-LIFE mark a key data overhang for the sector, and investors should watch for top-line and detailed readouts once they post to the ClinicalTrials portal, where the study remains recorded and updated.
To learn more about NVO’s potential, visit the Novo Nordisk drug pipeline page.